Dicerna Pharmaceuticals PT Lowered to $48.00 (DRNA)
Leerink Swann reduced their price target on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) from $60.00 to $48.00 in a research note issued on Wednesday, American Banking News reports. Leerink Swann’s price target points to a potential upside of 189.16% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Zacks initiated coverage on shares of Dicerna Pharmaceuticals in a research note on Wednesday, March 5th. They set a “hold” rating on the stock. Separately, analysts at Stifel Nicolaus initiated coverage on shares of Dicerna Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $53.00 price target on the stock. Finally, analysts at Robert W. Baird initiated coverage on shares of Dicerna Pharmaceuticals in a research note on Monday, February 24th. They set a “neutral” rating and a $41.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Dicerna Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $44.33.
Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) traded down 4.04% on Wednesday, hitting $15.93. 75,860 shares of the company’s stock traded hands. Dicerna Pharmaceuticals has a 52-week low of $15.00 and a 52-week high of $46.00. The stock has a 50-day moving average of $20.56 and a 200-day moving average of $29.52. The company’s market cap is $282.8 million.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Tuesday, May 13th. The company reported ($1.02) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.52) by $0.50. On average, analysts predict that Dicerna Pharmaceuticals will post $-1.89 earnings per share for the current fiscal year.
Dicerna Pharmaceuticals, Inc is a biopharmaceutical company. The Company focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.